News
The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...
U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...
Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...
Explore more
Privacy and information commissioners from Canada and the U.K. will reveal the findings of their investigation into the 23andMe data breach.
The stock's fall snapped a two-day winning streak.
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...
Mr Mathew Ogieva, a U.S.-based Nigerian and visionary in geoscience and data innovation, has continued to leave an indelible ...
Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.
A 23andMe booth at a genealogical event. The Canadian and British commissioners found the company did not have adequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results